NEW YORK, July 16, 2018 /PRNewswire/ -- If you want a free Stock Review on CBIO, COOL, CVM, and DARE sign up now at https://stocktraderreport.com/registration/.On Friday, July 13, 2018, with six out of nine sectors in green at the end of the trading sessions, US markets experienced broad based gains. Benchmark US indices were bullish at the end of last Friday's session - NASDAQ
On Friday, shares in USA-headquartered Catalyst Biosciences Inc. recorded a trading volume of 316,527 shares. The stock ended at $12.44, rising 2.64% from the last trading session. The Company's shares have gained 182.73% in the last twelve months. The stock is trading below its 50-day moving average by 39.08%. Furthermore, shares of Catalyst Biosciences, which focuses on developing medicines to address hematology indications, have a Relative Strength Index (RSI) of 35.26.
On July 10th, 2018, Catalyst Biosciences announced the appointment of Grant Blouse, Ph.D., as Vice President of translational research. Dr. Blouse was most recently principle scientist and project manager at Novo Nordisk A/S, Haemophilia Enzymology, where he led early and late stage hemophilia projects and drove the strategic evaluation of new therapeutic areas in the rare disease space. Get the full research report on CBIO for free by clicking below at: https://stocktraderreport.com/registration/?symbol=CBIO PolarityTE
USA-based PolarityTE Inc.'s stock finished last Friday's session 4.68% lower at $23.63. A total volume of 998,195 shares was traded, which was above their three months average volume of 830.06 thousand shares. The Company's shares have gained 44.00% over the previous three months. The stock is trading above its 200-day moving average by 1.04%. Furthermore, shares of PolarityTE, which operates as commercial-stage biotechnology and regenerative biomaterials company in the US, have an RSI of 41.56.
On July 02nd, 2018, PolarityTE announced that Peter Cohen will join its Board of Directors. Mr. Cohen is well known within the investment community having previously served on the Board of Directors at the NYSE, as well as previously serving as the CEO and Chairman of the Board of Cowen Inc., Shearson Lehman Cowen, and Republic New York Securities. COOL's complimentary research coverage is a few simple steps away at: https://stocktraderreport.com/registration/?symbol=COOL
At the close of trading on Friday, shares in USA-based CEL-SCI Corp. saw a drop of 0.95%, ending the day at $1.04. The stock recorded a trading volume of 400,284 shares. The stock is trading below its 50-day moving average by 58.79%. Moreover, shares of CEL-SCI, which engages in the research and development of drugs and vaccines, have an RSI of 28.74.
On July 02nd, 2018, CEL-SCI announced that it has closed its previously announced registered direct offering and concurrent private placement with institutional investors. The Company has received gross proceeds of approximately $5 million. Register for your free research report on CVM at: https://stocktraderreport.com/registration/?symbol=CVM
USA-headquartered Daré Bioscience Inc.'s shares ended the day 1.16% higher at $1.30 with a total trading volume of 98,684 shares. The stock has gained 39.37% in the previous three months. The Company's shares are trading above their 50-day moving average by 6.67%. Additionally, shares of Daré Bioscience, which focuses on developing and marketing women's reproductive health products in the US, have an RSI of 53.01. Stock Trader Report's downloadable research report on DARE is available at: https://stocktraderreport.com/registration/?symbol=DARE
Stock Trader Report:
Stock Trader Report (STR) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. STR has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
STR has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by STR. STR is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
STR, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. STR, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, STR, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither STR nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://stocktraderreport.com/privacy-policy/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: firstname.lastname@example.org Phone number: 917-979-2038Office Address: 22/F. 3 Lockhart Road, Wanchai Hong Kong
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/free-technical-briefing-on-biotechnology-stocks----catalyst-biosciences-polarityte-cel-sci-and-dare-bioscience-300681185.html
SOURCE Stock Trader Report
Subscribe to our Free Newsletters!